HH-2853 is under clinical development by Shanghai Haihe Biopharma and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HH-2853’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HH-2853 overview

HH-2853 is under development for the treatment of relapsed/refractory follicular lymphoma, peripheral T-cell lymphoma, diffuse large b-cell lymphoma, metastatic solid tumor, epithelioid sarcoma. It is administered through oral route. It targets the enzymes Histone-lysine N-methyl transferase EZH1 and EZH2 and Polycomb Repressive Complex 2 (PRC2).

It was under development for the treatment of natural killer cell lymphomas, angioimmunoblastic T-Cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) or Immunoblastic lymphadenopathy.

Shanghai Haihe Biopharma overview

Shanghai Haihe Biopharma (Haihe Biopharma) is a biotechnology company. Haihe Biopharma’s product portfolio comprises glumetinib, RMX3001, CYH33, AL3810, HH2853, HH2710, HH30134, HH2301, HH3806, HHHN, HHANT, HHOS, ON101 and HHMT. The company offers its products in the therapeutic areas of lung cancer, breast cancer, gastric cancer, solid tumor and Lymphoma among others. Haihe Biopharma is headquartered in Shanghai, Pu Dong, China.

For a complete picture of HH-2853’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.